(0)
XClinical, a leading vendor of eClinical software has announced a merger with France-based Carenity, a social platform supporting patients and caregivers worldwide, and Fortress Medical Systems, the US-based vendor of Clindex, an integrated CTMS and EDC system. All three companies are long-established, leading providers in their respective markets. The group is financed by German Private Equity firm BID Equity. Together, the three businesses will form a new, innovative data science company, powered by cutting edge technology. The group brings best in class data science and eClinical software solutions together, delivering end-to-end coverage of the clinical development process for their 150+ customers in over 20 countries, including US, Germany, France, UK, Italy, Japan and China.
Search jobs 12-Jan-2021 Celiac Disease Treatment Market 2021 Global Industry Growth, Trends, Share, COVID-19 Impact Analysis, and Demands Research Report| Amgen, Amneal Pharmaceuticals LLC., BioLineRx, Calypso Biotech
Celiac Disease Treatment Market 2020 Industry Research Report gives vital information then analytical data of industry Size, Share, Growth, Key Players then forecast. Furthermore it provides development trends and marketing channels analysis. Finally the feasibility of new investment projects are assessed and overall Research conclusions offered. This Report also presents product specification, manufacturing process, and product cost structure. The growth of the Celiac Disease Treatment market was mainly driven by the increasing R&D spending across the world, however latest COVID scenario and economic slowdown have changed complete market dynamics. The Celiac Disease Treatment report is prepared by taking into account th
This oncologic clinical trial evaluates the efficacy and safety of the CDK 4/6 Inhibitor Abemaciclib in combination with endocrine therapy in high-risk early breast cancer patients
Cologne, Germany, 07.01.2021 – CANKADO, the leading digital health application developers in Germany, assists the recently started clinical trial, ADAPTlate, organized by West German Study Group (WSG) to collect the Patient Reported Outcomes (PROs) by the CANKADO ePRO tool. The clinical trial already enrolled the first patients who are using the CANKADO e-Health system as part of the study to monitor their Quality of Life (QoL). The trial aims to gain further knowledge on the efficacy and safety of the Abemaciclib treatment in combination with endocrine therapy versus standard endocrine therapy in HR+/HER2- early breast cancer patients with high risk for disease recurrence.
Bioclinica Acquires Saliency to Accelerate Digital Diagnostic Development
New AI integration dramatically speeds medical image interpretation and model creation within Bioclinica s imaging platform
News provided by
Share this article
Share this article
PRINCETON, N.J., Jan. 6, 2021 /PRNewswire/ Bioclinica, an integrated solutions provider of clinical life science and technology expertise, today announced that it has acquired Silicon Valley-based Saliency. Bioclinica will integrate the company s advanced AI technology into its Imaging Platform to support a growing portfolio of pharmaceutical and medical device clients. The integration will dramatically accelerate image QC and interpretation, enabling rapid development of digital diagnostics and digital therapeutics.
IoT in Healthcare Market 2020 | Growth, Opportunities and Demand with Competitive Landscape and Analysis Research Report 2025 marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.